The #Pelthos Team is excited to announce the establishment of our Board of Directors. https://lnkd.in/eM4JTDnY
Pelthos Therapeutics’ Post
More Relevant Posts
-
Biophytis Strengthens its Management Team with the Appointment of its Chief Business Officer
Biophytis Strengthens its Management Team with the Appointment of its Chief Business Officer
pharmiweb.com
To view or add a comment, sign in
-
The year is nearly over, and it is time to reflect on the events of the past 12 months. Take a look at our latest blog post to get an overview of Senorics’ highlights of 2023. We wish you a great start into the new year! 🎇🥂 #materialsensing #NIR #team #review #blog #happynewyear
Reviewing 2023: What happened at Senorics in the past 12 months?
blog.senorics.com
To view or add a comment, sign in
-
Spherix Global Insights Appoints Dan Barton CEO - https://lnkd.in/gUKMic9m Follow #citybiz on LinkedIn - https://lnkd.in/eBgXKiz8 Spherix Global Insights
Spherix Global Insights Appoints Dan Barton CEO
https://www.citybiz.co
To view or add a comment, sign in
-
A first step in our M&A journey to strengthen our existing and best-in-class tides platform 🔥🔥🔥🔥
Proud to announce today our first M&A deal through the signature of an agreement to purchase 100% of the shares of BianoGMP GmbH, an oligonucleotide based CDMO. 🏆 Biano will reinforce our operations in the fast-paced oligonucleotide market by adding strong preclinical and early clinical capabilities, complementary with our existing larger scale footprint in Frankfurt. 🧬🔬 Kudos to all the colleagues who worked tremendously to make this project possible 💪 For more details about the transaction, see below ⬇️ https://lnkd.in/esYXJwhj #M&A #acquisition #CDMO
To view or add a comment, sign in
-
-
CEO and Founder of Genoplex.ai | Comms Committee @ ASGCT | Host of Rx for Biotech Podcast & TEDx Speaker
Check out this webinar with Chris Dokomajilar on January 16th to see what the year may look like for biopharma dealmaking in 2024! #venturecapital #biotech #biopharma #pharma #dealmaking #2024predictions
Join DealForma and Inpart for a look at how 2023 wrapped up and what is ahead for biopharma dealmaking in 2024. To kick-off a new year in partnering, Chris Dokomajilar, founder and CEO of DealForma, joins Inpart in this exclusive webinar. Reserve your free seat! https://lnkd.in/g7cTNFji
To view or add a comment, sign in
-
-
Following our recent acquisition of Reach Separations, here’s what Peter Ridgway, Business Development Director at Reach Separations, had to say: "Becoming part of the CatSci Ltd Group will enhance and strengthen Reach Separations’ ability to deliver excellence in chromatography. Integrating our technologies and expertise across the discovery and development landscape will provide a one-stop-shop for analysis and purification, giving the client a variety of options to progress the journey of their asset. As one of the founders of Reach Separations, I am delighted to join forces with CatSci to deliver strong growth and expand separation science into new marketplaces." This strategic acquisition marks a significant milestone for CatSci and enhances our ability to deliver programmes where rapid purification by chromatography is often essential to expediting clinical development. Together with Reach, we will drive forward our shared mission to deliver excellence in medicines development. Learn more about how this acquisition will solve our customers' separation science challenges: https://lnkd.in/ebprErGt #ExcellenceInMedicinesDevelopment #ProudToBeCatSci #DrugDevelopment #MedicinesDevelopment
To view or add a comment, sign in
-
-
Ziccum had an intensive schedule of meetings at Nordic Life Science Copenhagen Nov 29–30. CEO Ann Gidner and Chairman Fredrik Sjövall were invited to partnering meetings with new interested prospects and attended valuable follow-up meetings. CEO: ‘the knowledge of our offering is high and we expect to pursue many dialogues initiated here. It’s very satisfying we could move dialogues to a more strategic level with large corporation counterparts. We’d like to thank our industry colleagues for an engaging, well-attended event” https://lnkd.in/dq4pff64 #nlsdays #biologics #biopharmaceuticals #formulatiion #vaccines #thermostablevaccines
Ziccum move dialogues to next level at NLS Copenhagen
ziccum.com
To view or add a comment, sign in
-
Director & Co-Founder @ Unio Search | Talent Solutions for #CRO #CDMO #Biopharma #Clinical Technology | DEI Champion |
Whilst its been a tough year thus far, its great to see some positive news regarding investment into the clinical research sector! PE firm Permira, who already have some big CDMO names in their healthcare portfolio with the likes of Quotient Sciences and Cambrex to name a few, seem to be diversifying and adding CRO capabilities with the acquisition of ERGOMED for a whopping £703M...could we potentially see a merger in the future to create a 'one stop shop'? Either way there are exciting times ahead for Ergomed, lets watch this space. #mergersandacquisitions #cro #cmo #cmlifescience #clinicalresearch #clinicaltrials #growth #ergomed #permira
UK’s Ergomed agrees £703m takeover by private equity firm Permira
thetimes.co.uk
To view or add a comment, sign in
-
WSB Investor Call | June 21, 2022 (Preview) Here's a preview of the investor call with David Maris and Sarepta Therapeutics CEO Douglas S. Ingram. Whether you own $SRPT or thinking of getting long, you can't miss this discussion. "Our goal here is to delve deeper into the implications of the approval and understand Sarepta's longer term objectives." - David Maris "This is an enormous moment for the company." - Doug Ingram Access the entire Investor Call on $SRPT and don't miss Doug's incredible insights near the end on the importance of corporate culture in his organizations. Click the link in the comments sections to access. Fantastic discussion gentlemen! #InvestSmarter
To view or add a comment, sign in
-
Fantastic series B fund raise to close out 2023! Exciting 2024 ahead for everyone at Sudo Biosciences as they take two of their best/first in class, next gen TYK2 inhibitors into clinic. #fundraise #researchanddevelopment #lifesciences #biotechnology #neurology #dermatology
Excited to announce our $116M Series B financing round co-led by Enavate Sciences and TPG which is investing in the company through TPG Life Sciences Innovations and The Rise Fund, with participation from Sanofi Ventures, Surveyor Capital (a Citadel company), Monograph Capital and Eventide Asset Management as well as existing investors Frazier Life Sciences and Velosity Capital. Read the full release: https://lnkd.in/edgkg4dg
Sudo Biosciences Raises $116M Series B Financing to Advance Potential Best-in-Class TYK2 Therapeutics Programs into the Clinic
businesswire.com
To view or add a comment, sign in
Business Development | RWE | Healthcare Data & Analytics
4moCongratulations!